Aerwave Medical, a Laidlaw Venture Partners portfolio company operating under Laidlaw & Company UK Ltd., develops interventional treatment options for Asthma, chronic obstructive pulmonary disease (COPD), and advanced lung disease. With an asthma market of 2.5 million people and a COPD market of four million people in the United States alone, Aerwave Medical aims to fulfill an unmet need for patients who are unresponsive to drug therapy, including inhaler compliance.
Founded in 2020, the Aerwave Medical team is led by CEO and Executive Chairman Jeff O’Donnell. In February 2021, Laidlaw Venture Partners announced its successful closing of a $4 million Series A financing round for the company. With an experienced executive team that has a proven track record of success, Aerwave Medical holds broad intellectual property in the COPD and asthma industry, with further developmental plans to treat severe cases in the future.